Nakamuta M - Search Results

1

Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma.

Enjoji M, Morizono S, Kotoh K, Kohjima M, Miyagi Y, Yoshimoto T, Nakamuta M. Enjoji M, et al. Among authors: nakamuta m. World J Gastroenterol. 2005 Sep 28;11(36):5685-7. doi: 10.3748/wjg.v11.i36.5685. World J Gastroenterol. 2005. PMID: 16237765 Free PMC article. Clinical Trial.

2

Anti-tolA antibody in non-A, non-B chronic liver disease.

Nakamuta M, Sugimura T, Kotoh K, Fukutomi T, Sakamoto S, Yamamoto M, Nawata H. Nakamuta M, et al. Fukuoka Igaku Zasshi. 1992 Oct;83(10):367-76. Fukuoka Igaku Zasshi. 1992. PMID: 1281459

3

High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma.

Nakamuta M, Ohashi M, Tabata S, Tanabe Y, Goto K, Naruse M, Naruse K, Hiroshige K, Nawata H. Nakamuta M, et al. Am J Gastroenterol. 1993 Feb;88(2):248-52. Am J Gastroenterol. 1993. PMID: 8380950

4

Soluble Arg-Gly-Asp peptides reduce collagen accumulation in cultured rat hepatic stellate cells.

Iwamoto H, Sakai H, Kotoh K, Nakamuta M, Nawata H. Iwamoto H, et al. Among authors: nakamuta m. Dig Dis Sci. 1999 May;44(5):1038-45. doi: 10.1023/a:1026633302985. Dig Dis Sci. 1999. PMID: 10235616

5

Serum level of interleukin-4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C.

Higashi N, Nakamuta M, Motomura K, Enjoji M, Sakai H, Nawata H. Higashi N, et al. Among authors: nakamuta m. J Hepatol. 1999 Aug;31(2):383. doi: 10.1016/s0168-8278(99)80242-6. J Hepatol. 1999. PMID: 10453958 Clinical Trial. No abstract available.

6

Self-regulation of type I collagen degradation by collagen-induced production of matrix metalloproteinase-1 on cholangiocarcinoma and hepatocellular carcinoma cells.

Enjoji M, Kotoh K, Iwamoto H, Nakamuta M, Nawata H. Enjoji M, et al. Among authors: nakamuta m. In Vitro Cell Dev Biol Anim. 2000 Feb;36(2):71-3. doi: 10.1290/1071-2690(2000)036<0071:SROTIC>2.0.CO;2. In Vitro Cell Dev Biol Anim. 2000. PMID: 10718360 No abstract available.

7

Transforming growth factor-alpha induces the differentiation of sarcomatoid cholangiocarcinoma cells.

Enjoji M, Nakashima M, Nakamuta M, Nawata H. Enjoji M, et al. Among authors: nakamuta m. Jpn J Cancer Res. 2000 Feb;91(2):223-30. doi: 10.1111/j.1349-7006.2000.tb00935.x. Jpn J Cancer Res. 2000. PMID: 10761710 Free PMC article.

8

Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth.

Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. Iwamoto H, et al. Among authors: nakamuta m. J Lab Clin Med. 2000 May;135(5):406-12. doi: 10.1067/mlc.2000.105974. J Lab Clin Med. 2000. PMID: 10811056

9

A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth.

Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. Iwamoto H, et al. Among authors: nakamuta m. J Hepatol. 2000 May;32(5):762-70. doi: 10.1016/s0168-8278(00)80245-7. J Hepatol. 2000. PMID: 10845663

10

Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappab signaling pathway in rat Kupffer cells.

Shimohashi N, Nakamuta M, Uchimura K, Sugimoto R, Iwamoto H, Enjoji M, Nawata H. Shimohashi N, et al. Among authors: nakamuta m. J Cell Biochem. 2000 Jun 12;78(4):595-606. J Cell Biochem. 2000. PMID: 10861857

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters